Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 1
2016 1
2017 2
2018 1
2019 5
2020 4
2021 4
2022 9
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
Coquan E, Penel N, Lequesne J, Leman R, Lavaud P, Neviere Z, Brachet PE, Meriaux E, Carnot A, Boutrois J, Castera M, Goardon N, Muller E, Leconte A, Thiery-Vuillemin A, Clarisse B, Joly F. Coquan E, et al. Ther Adv Urol. 2024 Feb 28;16:17562872241229876. doi: 10.1177/17562872241229876. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 38425504 Free PMC article.
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
Lequesne J, Joly F, Peron J, Ray-Coquard I, Hardy-Bessard AC, Selle F, Berton D, Follana P, Fabbro M, Lortholary A, Pujade-Lauraine E, Lefèvre-Arbogast S, Coquan E. Lequesne J, et al. Among authors: coquan e. J Natl Compr Canc Netw. 2023 May;21(5):473-479.e4. doi: 10.6004/jnccn.2022.7101. J Natl Compr Canc Netw. 2023. PMID: 37156482
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Thibault C, Fléchon A, Albiges L, Joly C, Barthelemy P, Gross-Goupil M, Chevreau C, Coquan E, Rolland F, Laguerre B, Gravis G, Pécuchet N, Elaidi RT, Timsit MO, Brihoum M, Auclin E, de Reyniès A, Allory Y, Oudard S. Thibault C, et al. Among authors: coquan e. Eur J Cancer. 2023 Jun;186:83-90. doi: 10.1016/j.ejca.2023.03.018. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37054556 Clinical Trial.
Baseline quality of life and chemotherapy toxicities in patients with early breast cancer.
Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, Vaz Luis I, Charles C, Lemogne C, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Petit T, Dalenc F, Rouanet P, Lemonnier J, Everhard S, Cottu P, Joly F. Licaj I, et al. Among authors: coquan e. Cancer. 2023 Apr 1;129(7):1085-1095. doi: 10.1002/cncr.34643. Epub 2023 Jan 15. Cancer. 2023. PMID: 36642837 Free article.
TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E, Clarisse B, Lequesne J, Brachet PE, Nevière Z, Meriaux E, Bonnet I, Castera M, Goardon N, Boutrois J, Travers R, Joly F, Grellard JM, Thiery-Vuillemin A. Coquan E, et al. BMC Cancer. 2022 Nov 24;22(1):1213. doi: 10.1186/s12885-022-10216-z. BMC Cancer. 2022. PMID: 36434554 Free PMC article. Clinical Trial.
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mourksi NE, Dalban C, Colombe-Vermorel A, Odeyer L, Simioni V, Frenel JS, Fabbro M, Bazan F, Abadie-Lacourtoisie S, Coquan E, Martinez S, Garin G, Tabone-Eglinger S, Treilleux I, Chabaud S, Pérol D, Ray-Coquard I, Heudel PE, Diaz JJ, Marcel V. Mourksi NE, et al. Among authors: coquan e. Mol Oncol. 2023 Jan;17(1):27-36. doi: 10.1002/1878-0261.13340. Epub 2022 Dec 7. Mol Oncol. 2023. PMID: 36370117 Free PMC article.
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L, Dinart D, Delaunay B, Fléchon A, Saldana C, Lefort F, Gravis G, Thiery-Vuillemin A, Cancel M, Coquan E, Ladoire S, Maillet D, Rolland F, Boughalem E, Martin S, Laramas M, Crouzet L, Abbar B, Falkowski S, Pouessel D, Roubaud G. Meynard L, et al. Among authors: coquan e. Eur J Cancer. 2022 Nov;175:43-53. doi: 10.1016/j.ejca.2022.08.014. Epub 2022 Sep 8. Eur J Cancer. 2022. PMID: 36088671
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C. Coutzac C, et al. Among authors: coquan e. Dig Liver Dis. 2022 Oct;54(10):1335-1341. doi: 10.1016/j.dld.2022.07.008. Epub 2022 Jul 28. Dig Liver Dis. 2022. PMID: 35907691 Free article. Clinical Trial.
30 results